PubMed Trending Research Digest — June 26, 2026

A curated digest of 94 trending PubMed articles, automatically categorised and summarised across 77 research areas.

Jump to category

Antipsychotic response biomarkers (neurochemistry) Antiplatelet therapy optimization in PCI (bleeding vs efficacy) Inflammation-modified cardiovascular risk (Lp(a), CAD, aortic stenosis) Cutaneous adverse drug reactions (immune/biologic therapies) Targeted radiopharmaceutical therapy (alpha therapy, PET imaging) Genetics of alcohol toxicity and neuroinflammation Mucosal immunity and viral infection prevention (IgA, norovirus) Spatial immunology in autoimmune disease (RA macrophage–fibroblast niche) Host–virus post-translational control of antiviral restriction (SMCHD1, HSV-1) Multiplex protein mapping / proteome tagging methods Fungal pathogen life-cycle regulation (meiosis in Cryptococcus) Viral engineering and genome expression mapping (SARS-CoV-2 extra genes) Tumor suppressor–metabolism axes in cancer (p53–METTL5–mitochondria) Cancer immunotherapy engineering (TCR-mimic bispecifics, CAR T targets) Inflammasome regulation and phase separation (ASC, DDX6) Cancer immunometabolism and cachexia (immune-driven catabolism) AI/biomarkers for immunotherapy response (imaging, proteomics, spatial immune states) Spatial immune microenvironments in metastasis (brain metastases, macrophage escape) Pulmonary arterial hypertension treatment de-escalation (sotatercept/prostacyclin) JAK inhibition and immune remodeling in inflammatory skin disease (PPP) CAR-T optimization (lymphodepletion regimens, long-term outcomes) Type 2 inflammation therapeutics (dupilumab, eosinophilic gastritis) Obesity epidemiology and inequality (UK trends) GLP-1 and body composition / lean mass preservation GLP-1 and renal outcomes in obesity with CKD/hypertension H. pylori eradication regimen optimization (antibiotic resistance, lactoferrin) Digital/scalable psychotherapy for chronic pain (CBT-CP delivery) Cardiovascular trial endpoints (right ventricle metrics) Neuroimaging-guided neuromodulation (aTMS targeting) Genome editing in human embryos (base editing, NANOG) Bispecific therapy in hematologic malignancy (teclistamab regimens) Long-term CAR T durability and guidelines (tisagenlecleucel, HL EHA guidance) Risk stratification in lymphoma (TI-CH, CD79B expression, pCR relapse TNBC) Precision oncology modeling (virtual tumors, personalized combinations) Neurodegeneration mechanisms (TDP-43 proteostasis, autophagy, ALS/FTD stress) Plant development and mechanobiology (stomata, meristems, PPB) Mitochondrial stress–epigenetics–longevity (C. elegans IRE1/FUBL-3) Neural circuits for social threat (PVN oxytocin projections) Steroid/sterol hormone control in plants (brassinosteroid–WUS) Protein aggregation determinants in ALS (sTDP-43 steric zippers) Alcoholic liver disease lipid remodeling (GPAM, mitochondrial dysfunction) SUMOylation as cancer vulnerability (Pax6 sumoylation) mRNA-LNP vaccine immunology (innate/adaptive mechanisms) Exercise + GLP-1 vascular effects during weight maintenance COPD exacerbation biomarkers (ECM turnover, neutrophil elastase fragments) Immune thrombocytopenia thrombopoiesis (S100A8/A9, TLR4/JNK/GATA1) Ciliary coordination biology (RGS22 radial spoke) Biomarkers of immune checkpoint resistance (melanoma proteomics/cytometry) Parkinson’s disease genetics (MAPT haplotypes) Human-specific necrosis pharmacology (TRPM4 activation by Necrocide 1) Microbiome–metabolite–cancer axis (Fusobacterium/decanoic acid, neutrophils) Post-thrombectomy stroke therapy (tirofiban) Heart failure therapeutics (ghrelin agonist/calcium-sensitizing inotrope AC01) Severe asthma remission and real-world burden (registry analysis) Microbiota metabolite effects on insulin/mitochondria (phenylacetylation, SIRT3) Human developmental patterning (primitive streak, gastrulation maps) Future-oriented behavioral interventions for cardiovascular health Traditional medicine for vascular integrity in CCM (CDDP) Mitochondrial regulators in cancer (prohibitin PHB1/PHB2 review) Peanut allergy prevention and immunotherapy (early introduction) Obesity pharmacotherapy quality of weight loss (lean mass/bone) Extracellular mitochondria in systemic injury after TBI Pulmonary fibrosis targeted degradation delivery (inhalable PROTAC nanococktail) Genomic reanalysis automation for rare disease (Talos) STING activation sequence-function landscape Alternate genetic code / proteome diversity (alternate RNA decoding) ecDNA segregation mechanisms (H3K27ac readers) Microbial antibiotic biosynthetic genetics (Streptomyces megacluster) GPCR signaling control tools (β-arrestin modulators) In vitro immune cell differentiation (Tfr cells, TGF-β/IL-2) Human gastrulation spatial transcriptomics (pregastrula mapping) Metabolomics and brain health (cognition/MRI, Rotterdam Study) TB progression signatures in airway immune cells (household contacts) Viral emergence risk via receptor usage (merbecoviruses) Public health outbreak reporting (Bundibugyo virus DRC) Plant mechanosensitive asymmetric division (KAI1/PPB positioning) Cardiac death prediction from ECG (deep learning SCD biomarker)

Automated digest · 94 articles · 77 research areas · June 26, 2026

Overview

This week’s research is dominated by efforts to make therapies more precise—using biomarkers, imaging, and computational tools to predict who will benefit and when to change course. In oncology and immunotherapy, studies leveraged deep learning on biopsy slides, multimodal spatial immune profiling, and large-scale blood proteomics/cytometry to identify signatures of response and early resistance. In hematologic malignancies, multiple works refined risk stratification (e.g., tumor-infiltrating clonal hematopoiesis) and optimized treatment components (CAR-T lymphodepletion choices; bispecific induction regimens), while longer-term follow-up reports and practice guidelines emphasized durability and standardized, risk-adapted care.

A second major theme is mechanistic immunology and inflammation—spanning innate immune signaling, mucosal protection, and autoimmune remodeling. Work on inflammasome activation (ASC speck formation), antiviral restriction control via post-translational modifications, and cytokine-pathway targeting (eosinophilic gastritis with dupilumab; JAK1 inhibition in palmoplantar pustulosis) highlights how pathway-level understanding is translating into therapeutic strategies. Autoimmune and inflammatory disease studies further used spatial approaches to map cellular niches (RA macrophage–fibroblast interactions; brain metastasis macrophage escape), while mucosal IgA was shown to be necessary and sufficient for norovirus protection, underscoring that “where immunity acts” can matter as much as “which immunity.”

Finally, several studies connect systemic physiology to disease risk and outcomes, often via imaging or multi-omic readouts. Cardiometabolic research addressed obesity and body composition (including regional fat distribution and lean-mass considerations during GLP-1 therapy), cardiovascular risk refinement (inflammation modifying Lp(a) effects), and prognostic modeling in critical illness (CT sarcopenia plus inflammatory markers). Across infectious disease and public health, TB progression signatures in airway cells and outbreak-focused reporting on filoviruses emphasize the need for earlier detection and better stratification—while microbiome/metabolite studies (e.g., Fusobacterium–neutrophil chemotaxis; phenylacetylation–SIRT3/mitochondria) continue to reveal actionable biological links between environment and host vulnerability.

Antipsychotic response biomarkers (neurochemistry)

Cryo-electron microscopy structures of human cone visual pigments.

Researchers determined cryo-electron microscopy structures of the three human cone visual pigments—LWS-, MWS-, and SWS-opsins—each bound to a G protein and all-trans retinal in the presumed active state. The structures showed marked differences from rhodopsin, including a distinct counterion site in LWS/MWS and a ring of serines around the retinal in SWS-opsin. These high-resolution structures clarify the molecular basis of cone phototransduction and spectral tuning, informing mechanistic vision biology and potential interventions for cone-related disorders.

Peng Q, Li J, Jiang H et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Neurometabolites and Antipsychotic Response in Psychosis: A Mega-Analysis.

This mega-analysis used individual participant data from 18 studies to compare neurometabolite profiles in antipsychotic-responsive versus antipsychotic-nonresponsive psychosis participants. The key finding was that specific neurometabolite differences distinguished nonresponse from response, supporting neurometabolite-based prediction of antipsychotic outcome. These results are clinically significant because they identify neurobiological markers that could improve prognosis and guide development of targeted treatments for antipsychotic nonresponse in psychosis.

King B, Bojesen KB, Crisp C et al. · JAMA psychiatry · (2026) · View on PubMed ↗

Antiplatelet therapy optimization in PCI (bleeding vs efficacy)

A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis.

This phase 3, open-label, pragmatic randomized noninferiority trial studied a 6-month pulmonary rifampicin-resistant tuberculosis regimen in South African participants aged ≥6 years, comparing bedaquiline plus linezolid plus delamanid plus levofloxacin (with or without clofazimine) for 6 months versus the then-current 9-month standard-of-care regimen. The key finding was that the 6-month strategy was noninferior to the 9-month standard-of-care approach for treating pulmonary rifampicin-resistant tuberculosis. If confirmed in broader implementation, this shorter all-oral/optimized regimen could improve safety, adherence, and programmatic feasibility for rifampicin-resistant TB care in high-burden settings.

Conradie F, Badat T, Poswa A et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis evaluated randomized clinical trials in high bleeding risk patients undergoing percutaneous coronary intervention (PCI) comparing abbreviated dual antiplatelet therapy (DAPT) durations (1–3 months) versus standard durations (6–12 months). The key finding was that shorter DAPT durations were associated with improved safety (reduced bleeding) without clear loss of efficacy compared with standard-duration DAPT. This is significant for clinical decision-making because it supports tailoring DAPT duration to bleeding risk in HBR patients after PCI.

Zito A, Landi A, Bhatt DL et al. · JAMA cardiology · (2026) · View on PubMed ↗

Inflammation-modified cardiovascular risk (Lp(a), CAD, aortic stenosis)

Regional fat distribution as a determinant of mortality in populations with left ventricular systolic dysfunction: challenging the obesity paradox.

The study evaluated whether regional fat distribution predicts mortality in people with left ventricular systolic dysfunction, challenging the “obesity paradox,” using UK Biobank Imaging Enhancement Programme participants with cardiac magnetic resonance (CMR)–defined left ventricular ejection fraction <50%. It found that specific patterns of adiposity measured by CMR-derived regional fat distribution were associated with mortality risk beyond what body mass index (BMI) captures. Clinically, this supports using regional fat phenotyping rather than BMI alone for risk stratification in heart failure patients with systolic impairment.

Khanna S, Ho W, Takeuchi F et al. · European journal of preventive cardiology · (2026) · View on PubMed ↗

Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis.

This cohort study in UK Biobank participants without prevalent coronary artery disease (CAD) or aortic valve stenosis (AS) tested whether inflammatory biomarkers modify lipoprotein(a) [Lp(a)]-associated risk for CAD and AS using plasma proteomic profiling. The key finding was that inflammatory biomarkers meaningfully modified the relationship between elevated Lp(a) and subsequent risk of CAD and aortic valve stenosis. This is scientifically and clinically significant because it helps explain heterogeneity in Lp(a) risk and suggests that inflammation status may refine risk stratification and future prevention strategies.

Mohammadnia N, Li L, Ezzat D et al. · JAMA cardiology · (2026) · View on PubMed ↗

Cutaneous adverse drug reactions (immune/biologic therapies)

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

This review article synthesized evidence on how biologics and small-molecule inhibitors contribute to cutaneous adverse drug reactions (cADRs), with emphasis on immune checkpoint inhibitors and other novel therapies. The key finding was that while many cADRs are self-limited, a measurable minority progress to severe, potentially fatal syndromes such as Stevens–Johnson syndrome/toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome. This is significant because it frames emerging mechanisms and therapeutic strategies for preventing, recognizing, and managing severe cutaneous toxicity in patients receiving modern anticancer and immune-modulating drugs.

Yin Y, Wang Y, Zhou J et al. · Drugs · (2026) · View on PubMed ↗

Targeted radiopharmaceutical therapy (alpha therapy, PET imaging)

FOLR1-targeted actinium-225-based alpha-particle therapy eliminates ovarian cancer.

The study evaluated folate receptor 1 (FOLR1)-targeted actinium-225 (225Ac) alpha-particle therapy using an anti-FOLR1 antibody in SKOV3 ovarian cancer xenografts with longitudinal PET imaging. FOLR1-targeted 225Ac produced marked tumor regression with high tumor-specific uptake by αFOLR1 in vivo. This supports FOLR1 as a clinically actionable target for 225Ac-based targeted alpha therapy in refractory ovarian cancer.

Singh N, Need E, Berndt A et al. · Science advances · (2026) · View on PubMed ↗

Genetics of alcohol toxicity and neuroinflammation

Common human ALDH1B1 and ALDH2 variants increase neuroinflammatory response to a single ethanol dose in mice.

The study examined how common human ALDH1B1 and ALDH2 variants affect neuroinflammatory responses to a single ethanol dose in mice, using double knock-in mice carrying ALDH1B1 loss-of-function (G193fs) and ALDH2*2 (E504K). Mice harboring both inactive ALDH1B1 and inactive ALDH2 variants showed increased neuroinflammatory responses after ethanol exposure compared with controls. These findings implicate combined ALDH1B1/ALDH2 genetic risk in ethanol-associated neuroinflammation and help refine human-relevant models of alcohol toxicity.

Seike T, Albuquerque RPE, Ferreira JCB et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

Mucosal immunity and viral infection prevention (IgA, norovirus)

IgA is necessary and sufficient to prevent norovirus infection in mice.

The study tested whether mucosal immunoglobulin A (IgA) is required and/or sufficient to prevent murine norovirus infection, and compared this with the role of CD8+ T cells and systemic vaccination. Intestinal IgA was necessary and sufficient for protection, CD8+ T cells were dispensable, and systemic vaccination induced neutralizing serum IgG but did not prevent enteric infection. This indicates that effective norovirus countermeasures likely need durable mucosal IgA rather than relying on serum IgG alone.

Ökten AB, Filler RB, Kung JL et al. · Science translational medicine · (2026) · View on PubMed ↗

Temperature and developmental stage govern intestinal susceptibility to human coronavirus 229E.

The study examined how temperature and developmental stage affect susceptibility of human intestinal epithelia to human coronavirus 229E using patient-derived human intestinal enteroids (HIEs) from fetal, pediatric, and adult donors. Infection dynamics differed by physiologic temperature (37°C vs 32°C) and by donor developmental stage, indicating that both factors modulate epithelial responses and viral replication. This work is significant for understanding why coronaviruses can produce gastrointestinal disease and for predicting infection risk across age groups and body sites.

Synowiec A, Lie LK, Owczarek K et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Spatial immunology in autoimmune disease (RA macrophage–fibroblast niche)

Transferrin in combination with induction chemotherapy improves outcomes in mouse models of acute myeloid leukemia.

The study used spatial transcriptomic profiling of rheumatoid arthritis (RA) patient synovium to define how SPP1hi (osteopontin-high) macrophages and nearby proliferating fibroblasts contribute to hyperplastic pannus remodeling. It found proliferating fibroblasts enriched near the synovial lining surface adjacent to SPP1hi macrophages, linking macrophage–fibroblast spatial organization to aggressive tissue expansion. This provides a mechanistic cellular niche model that could guide macrophage/osteopontin-targeted therapies to limit destructive RA remodeling.

Lopes M, Lemos F, Rocha L et al. · Science translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Host–virus post-translational control of antiviral restriction (SMCHD1, HSV-1)

SUMOylation and ubiquitination reciprocally regulate SMCHD1 antiviral activity against herpes simplex virus 1.

The study investigated how SUMOylation and ubiquitination reciprocally regulate the antiviral restriction factor SMCHD1 against herpes simplex virus 1 (HSV-1). SUMOylation of SMCHD1 promoted viral-genome association and enhanced antiviral activity, whereas the HSV-1 E3 ligase ICP0 induced SMCHD1 ubiquitination and proteasomal degradation to relieve restriction. This reveals a host–virus post-translational modification switch that could be exploited to bolster intrinsic antiviral defenses.

Tian X, Wang X, Wang S et al. · PLoS pathogens · (2026) · View on PubMed ↗ · Free PDF ↗

Multiplex protein mapping / proteome tagging methods

A pilot study for whole proteome tagging in Caenorhabditis elegans.

The pilot study developed and tested scalable whole-proteome tagging in Caenorhabditis elegans by introducing spectrally distinct fluorescent tags in pooled experiments. It tagged 30 genetic loci using three fluorophores with three tags introduced at a time, using essential genes selected from transcriptomics to span expression levels while assessing disruption of gene function. This provides a practical framework for genome-wide, multiplexed protein localization studies in a model organism.

Eroglu M, Hobert O · eLife · (2026) · View on PubMed ↗ · Free PDF ↗

Fungal pathogen life-cycle regulation (meiosis in Cryptococcus)

Identification of a master regulator Msd1 that governs meiotic entry in a global basidiomycete pathogen.

The study identified and characterized Msd1 as a master regulator governing meiotic entry in the basidiomycete pathogen Cryptococcus neoformans and related global basidiomycete lineages. It showed that Msd1 controls the transition into meiosis, a process linked to generating genetic diversity and supporting host adaptation. This advances understanding of how fungal pathogens initiate meiosis and may reveal targets to interfere with cryptococcal life-cycle progression.

Zheng F, Cao Y, Chen H et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Viral engineering and genome expression mapping (SARS-CoV-2 extra genes)

Extra gene coding capacity of SARS-CoV-2 provides a virus engineering platform for in vitro and in vivo applications.

The study explored SARS-CoV-2’s extra gene coding capacity by inserting an additional reporter gene at every intergenic region to map extra gene expression in vitro and in vivo. It delineated the full scheme of extra gene expression and identified a genomic location that stably expresses the inserted reporter. This establishes a virus engineering platform for programmable SARS-CoV-2-based in vitro and in vivo applications.

Kim T, Biswas A, Kandel S et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Tumor suppressor–metabolism axes in cancer (p53–METTL5–mitochondria)

p53 overrides METTL5 loss-induced tumor suppression via mitochondrial respiration.

The study examined how wild-type p53 counteracts tumor suppression caused by loss of the methyltransferase METTL5 via effects on mitochondrial respiration in non-small cell lung cancer (NSCLC). METTL5 depletion impaired NSCLC proliferation and migration, but p53 overrode this regression by sustaining mitochondrial respiration, with p53-null cells showing stronger tumor regression. This uncovers a p53–METTL5–mitochondrial respiration axis that may influence therapeutic responses in METTL5-deficient tumors.

Li G, Li Q, Zhang J et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Cancer immunotherapy engineering (TCR-mimic bispecifics, CAR T targets)

AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy.

The study developed an AI-driven pipeline that integrates single-cell RNA sequencing datasets from human skin cancer and healthy tissue, using large language models to nominate CAR T cell targets and then experimentally validate candidates, focusing on glycoprotein non-metastatic melanoma protein B (GPNMB). The approach identified GPNMB as a promising multi-cancer CAR T target and supported its therapeutic potential across cancer contexts. This work addresses the CAR T target-identification bottleneck by combining scRNA-seq, public dataset filtering, and LLM prioritization to accelerate development of next-generation multi-cancer CAR T therapies.

Baker DJ, Frommer LM, Uslu U et al. · Cell · (2026) · View on PubMed ↗

TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy.

The study developed a first-in-class TCR-mimic bispecific nanobody-based T cell engager (TCRm Bi-NbTE) to target intracellular tumor antigens using a modular VHH–VHH platform. The key finding was that the TCR-mimic bispecific nanobody design enabled T cell engagement against intracellular targets while avoiding instability and extracellular-target limitations typical of scFv-based bispecific TCEs. This provides a clinically relevant immunotherapy engineering strategy to expand bispecific T cell engager antigen scope beyond extracellular proteins.

Ding Z, Sun S, Yang X et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Inflammasome regulation and phase separation (ASC, DDX6)

RNA helicase DDX6 governs ASC speck formation in P-bodies and the transition to stress granules via phase separation during inflammasome activation.

This work investigated how the RNA helicase DDX6 regulates ASC speck formation during inflammasome activation in vivo. The key finding was that DDX6 interacts with ASC (identified by immunoprecipitation–mass spectrometry) and promotes NLRP3 and AIM2 inflammasome activation by facilitating ASC recruitment and liquid–liquid phase separation in P-bodies to drive ASC speck formation. Scientifically, it identifies DDX6 as a mechanistic scaffold/processing factor linking P-body assembly to inflammasome signaling, suggesting a potential target to modulate inflammatory disease pathways.

Mao R, Liu Y, Fan Z et al. · Cell discovery · (2026) · View on PubMed ↗ · Free PDF ↗

Cancer immunometabolism and cachexia (immune-driven catabolism)

This review synthesized evidence on cancer-related cachexia as an immunometabolic, multi-organ process rather than a purely nutritional deficit. The key finding was that immune-driven inflammatory cascades, neuro-immune circuits, and tissue cellular plasticity converge to drive muscle and adipose catabolism, with nutrient competition between tumor cells and host immunity accelerating tissue degradation. Clinically, reframing cachexia around immune regulation highlights new therapeutic opportunities targeting immune-metabolic mechanisms.

Xue J, Lu T, Yang K et al. · Trends in cancer · (2026) · View on PubMed ↗

AI/biomarkers for immunotherapy response (imaging, proteomics, spatial immune states)

Breastfeeding shapes a unique tumor-immune landscape in pregnancy-associated breast cancer from GEICAM-EMBARCAM study.

This study examined how breastfeeding versus gestation versus post-weaning physiological stages shape the tumor-immune landscape in pregnancy-associated breast cancer (PABC) using molecular profiling in 106 breast cancer cases (57 PABC patients) from the GEICAM-EMBARCAM study. Using NanoString gene expression (BC360) and CIBERSORTx immune deconvolution, it defined shared and stage-specific tumor and immune features associated with reproductive context. Clinically, these stage-resolved immune signatures may reveal therapeutic vulnerabilities and help tailor treatment strategies for PABC by reproductive stage.

Peña-Enríquez R, Guerrero-Zotano Á, Bermejo B et al. · Breast cancer research : BCR · (2026) · View on PubMed ↗ · Free PDF ↗

Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.

This study evaluated whether AI-guided analysis of pretreatment and on-treatment tumor biopsies can predict response to pembrolizumab in rare tumors. The key finding was that deep learning–based quantification of intratumoral tumor-infiltrating lymphocyte (iTIL) density and tumor content (TC) from H&E slides (using Lunit SCOPE IO) associated baseline iTIL and on-treatment changes with pembrolizumab outcomes across 84 patients and 10 rare-tumor cohorts. This is significant because it provides a scalable imaging biomarker approach to stratify immunotherapy benefit in rare cancers where conventional predictors are limited.

Derbala MH, Stephen B, Hwang W et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Spatial immune microenvironments in metastasis (brain metastases, macrophage escape)

Spatial immune atlas of breast cancer brain metastasis reveals CD163+ macrophage reprogramming associated with immune escape.

This study mapped the spatial immune microenvironment of human breast cancer brain metastases using high-plex imaging mass cytometry (IMC) integrated with single-cell RNA-seq and spatial transcriptomics. The key finding was that CD163+ macrophages show reprogramming patterns associated with immune escape in brain metastasis tissue compared with breast tumor contexts. Scientifically, it defines a spatially resolved macrophage state linked to immune evasion, supporting macrophage-targeted strategies for brain metastatic disease.

Zhu J, Ye J, Ma Y et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Pulmonary arterial hypertension treatment de-escalation (sotatercept/prostacyclin)

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept.

This article described a practical approach to de-escalating prostacyclin-based therapy in patients with pulmonary arterial hypertension who were treated with sotatercept. The key finding was that in real-world clinical scenarios where patients demonstrate sustained improvement on sotatercept plus background therapy, clinicians can consider prostacyclin de-escalation using structured monitoring and risk assessment. Clinically, it aims to improve safety and decision-making when transitioning patients off intensive prostacyclin regimens.

Tasevac B, Cirulis MM, Dodson MW et al. · Chest · (2026) · View on PubMed ↗

JAK inhibition and immune remodeling in inflammatory skin disease (PPP)

Ivarmacitinib is associated with rapid clinical improvement and immune remodeling in palmoplantar pustulosis: A multi-center, single-arm clinical trial.

This multi-center, single-arm trial assessed ivarmacitinib (a selective JAK1 inhibitor) in patients with palmoplantar pustulosis (PPP) and evaluated immune remodeling as well as predictors of response. The key finding was that oral ivarmacitinib 4 mg daily produced rapid clinical improvement (PPPASI reduction at week 12) alongside measurable changes in peripheral T lymphocyte subsets, neutrophil phenotypes, and plasma proteomics. This is significant because it links JAK1 inhibition to immune pathway modulation in PPP and identifies baseline features that may help forecast treatment response.

Xu Z, Chen W, Du J et al. · Journal of the American Academy of Dermatology · (2026) · View on PubMed ↗ · Free PDF ↗

CAR-T optimization (lymphodepletion regimens, long-term outcomes)

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

This JAMA Oncology study analyzed long-term outcomes in patients with platinum-sensitive recurrent ovarian cancer (PS-ROC) who achieved exceptional response to maintenance PARP inhibitors, and explored genotype–phenotype associations. The key finding was that exceptional responders can experience durable long-term outcomes while also clarifying risks of late progression and hematologic toxicities such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Clinically, the results inform decisions about optimal PARP inhibitor duration and surveillance strategies in exceptional responders.

Haggstrom L, Lee YC, Barretina-Ginesta MP et al. · JAMA oncology · (2026) · View on PubMed ↗

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

This study compared fludarabine-based versus bendamustine-based lymphodepleting chemotherapy prior to CD19 CAR-T in relapsed/refractory large cell lymphoma using real-world CIBMTR data. The key finding was that outcomes differed between fludarabine and bendamustine lymphodepletion in patients receiving commercial CD19 CAR-T products (including axicabtagene ciloleucel and tisagenlecleucel) from 2017–2023. Clinically, it informs selection of lymphodepletion regimens to optimize CAR-T efficacy and persistence in LBCL.

Ahmed N, Ali A, Kim S et al. · Transplantation and cellular therapy · (2026) · View on PubMed ↗

Type 2 inflammation therapeutics (dupilumab, eosinophilic gastritis)

This randomized, double-blind, placebo-controlled phase 2 trial evaluated dupilumab versus placebo for eosinophilic gastritis (DEGAS) in adolescents and adults. The key finding was that dupilumab, which blocks IL-4 and IL-13 signaling, improved histologically active eosinophilic gastritis outcomes over a 12-week blinded period and was further assessed for longer-term safety and efficacy in a 24-week open-label extension. Clinically, it provides evidence for targeting type 2 inflammation as a treatment strategy in a condition with no approved therapies.

Gonsalves NP, Dellon ES, Kliewer KL et al. · The lancet. Gastroenterology & hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

Obesity epidemiology and inequality (UK trends)

Whole-population trends in obesity across dimensions of inequality in England, 2019-25: a retrospective, longitudinal cohort study of 54 million adults.

This retrospective, longitudinal cohort study analyzed whole-population trends in obesity across multiple dimensions of inequality in England from 2019–2025 using NHS electronic health records. The key finding was that obesity incidence and prevalence changed over time and varied by age, sex, socioeconomic status, ethnicity, and geography, with patterns reflecting intersecting inequalities after the COVID-19 period. Public-health significance: it identifies where obesity burdens are widening or narrowing, supporting targeted prevention policies for groups most affected by inequality.

Fletcher RA, Conrad N, Rockenschaub P et al. · The lancet. Diabetes & endocrinology · (2026) · View on PubMed ↗ · Free PDF ↗

CT-Assessed Sarcopenia Combined with Laboratory Inflammatory Markers for Outcome Prediction in Critically Ill, Pulmonary, and Geriatric Patients: A Systematic Review and Meta-Analysis.

The study systematically reviewed and meta-analyzed whether computed tomography (CT)–assessed sarcopenia, alone or combined with laboratory inflammatory markers (C-reactive protein [CRP], interleukin-6 [IL-6], and neutrophil-to-lymphocyte ratio [NLR]), predicts outcomes in critically ill, pulmonary, and geriatric patients. The key finding was that CT sarcopenia and inflammatory markers have prognostic value, and combining them improves outcome prediction compared with either approach alone. This is significant because it supports more accurate, multimodal risk models for mortality, mechanical ventilation duration, and ICU length of stay in high-risk hospitalized populations.

Elgazzar YA, Abdelrazek M, Ghozzy OAM et al. · La Clinica terapeutica · (2026) · View on PubMed ↗

GLP-1 and body composition / lean mass preservation

Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies.

This narrative review synthesized evidence on body composition outcomes during GLP-1-based obesity pharmacotherapy, focusing on whether treatment-related weight loss leads to clinically meaningful lean mass loss and how to preserve muscle and function. The review concluded that nutrition, supplementation, exercise, and monitoring strategies can mitigate muscle loss and support bone health and nutritional adequacy during GLP-1-based treatment. Scientifically and clinically, it provides an actionable framework for optimizing “quality of weight loss” rather than weight loss magnitude alone.

Šantić R, Martinović L, Pavlović N et al. · Metabolites · (2026) · View on PubMed ↗ · Free PDF ↗

GLP-1 and renal outcomes in obesity with CKD/hypertension

Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.

The study conducted a systematic review and meta-analysis to assess long-term safety and renal outcomes of semaglutide, a GLP-1 receptor agonist, in non-diabetic adults with obesity plus chronic kidney disease (CKD) or hypertension. It evaluated changes in BMI, blood pressure, estimated glomerular filtration rate (eGFR), and albuminuria and synthesized evidence on adverse events and renal endpoints. The clinical significance is that it informs whether semaglutide can provide renal and cardiometabolic benefit with acceptable safety in non-diabetic CKD/hypertension populations where evidence has been limited.

Elganyny MKE, Elganyni AKE, Maskji HA et al. · La Clinica terapeutica · (2026) · View on PubMed ↗

H. pylori eradication regimen optimization (antibiotic resistance, lactoferrin)

Helicobacter pylori Eradication in the Era of Rising Antibiotic Resistance: A Randomized Controlled Comparison of Clarithromycin- and Levofloxacin-Based Triple Therapy with or without Lactoferrin.

The study randomized 160 adults with confirmed Helicobacter pylori infection to compare clarithromycin-based versus levofloxacin-based triple therapy, each with or without adjunctive lactoferrin, in an open-label 2×2 factorial design. The key finding was the relative impact of antibiotic choice and lactoferrin addition on H. pylori eradication rates and safety in the setting of rising antibiotic resistance. This is clinically significant because it helps optimize first-line eradication regimens when clarithromycin resistance reduces standard triple therapy effectiveness.

Elganzory A, Baraka M, Elkholy AR et al. · La Clinica terapeutica · (2026) · View on PubMed ↗

Digital/scalable psychotherapy for chronic pain (CBT-CP delivery)

Self-Directed vs Clinician-Delivered Cognitive Behavioral Therapy for Chronic Pain: A Randomized Clinical Trial.

The study compared self-directed cognitive behavioral therapy for chronic pain (CBT-CP) with asynchronous, personalized feedback versus clinician-delivered CBT-CP in a pragmatic randomized clinical trial of 764 patients with chronic musculoskeletal pain across 9 US Veterans Health Administration (VHA) sites. The key finding was the effectiveness of the self-directed approach under usual clinical conditions relative to clinician-delivered CBT-CP. This is significant because it addresses access barriers to CBT-CP and could expand scalable, lower-cost treatment options for chronic pain in real-world settings.

Heapy AA, Driscoll MA, Edmond S et al. · JAMA · (2026) · View on PubMed ↗

Cardiovascular trial endpoints (right ventricle metrics)

Right Ventricular Metrics as End Points in Clinical Trials: A Review.

The article reviewed how right ventricular (RV) structure and function metrics can be used as endpoints in cardiovascular clinical trials, focusing on imaging and hemodynamic parameters. It highlighted current and emerging RV-focused endpoints and provided a framework for their development, validation, and implementation. Scientifically and clinically, this supports more sensitive trial endpoints that may improve efficiency and reduce sample sizes in studies of RV-relevant cardiovascular conditions.

Surkova E, Lakatos B, Kempton H et al. · JAMA cardiology · (2026) · View on PubMed ↗

Neuroimaging-guided neuromodulation (aTMS targeting)

Connectivity- vs Scalp-Based Targeting of Accelerated Transcranial Magnetic Stimulation for Depression: A Randomized Clinical Trial.

The study randomized participants with treatment-resistant depression to receive accelerated transcranial magnetic stimulation (aTMS) targeted either by functional connectivity neuroimaging or by scalp-based targeting. The key finding was the comparative effect size of connectivity-based versus scalp-based targeting on depressive outcomes. This is significant because it tests whether neuroimaging-guided circuit targeting improves clinical efficacy beyond simpler scalp-based approaches in aTMS delivery.

Taylor JJ, Kare MR, Haj-Darwish D et al. · JAMA psychiatry · (2026) · View on PubMed ↗

Genome editing in human embryos (base editing, NANOG)

Base editing reveals an essential role for NANOG in human embryogenesis.

The study used adenine base editing (ABE8e) to precisely perturb an exon splice donor site in human embryos to define the role of the transcription factor NANOG during early human embryogenesis. Base editing revealed that NANOG is essential for proper early developmental progression and lineage specification. These findings provide a safer, non-nuclease functional genomics strategy for human embryos and clarify NANOG’s causal role, informing regenerative medicine and infertility/pregnancy-loss research.

Bower OJ, R Orsi AE, McMahon R et al. · Nature · (2026) · View on PubMed ↗

Bispecific therapy in hematologic malignancy (teclistamab regimens)

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

This phase 2 pooled analysis evaluated teclistamab-based induction regimens in transplant-eligible, newly diagnosed multiple myeloma (NDMM), comparing teclistamab/daratumumab/lenalidomide (Tec-DR) versus teclistamab/daratumumab/lenalidomide plus bortezomib (Tec-DVR). The trial reported clinical efficacy outcomes for 49 patients across three cohorts receiving Tec-DR (arms A and A1) or Tec-DVR (arm B). The results support teclistamab-containing frontline strategies and help refine how to combine BCMA×CD3 bispecific therapy with daratumumab, lenalidomide, and bortezomib in transplant-eligible patients.

Raab MS, Weinhold N, Kortüm KM et al. · Nature medicine · (2026) · View on PubMed ↗

Long-term CAR T durability and guidelines (tisagenlecleucel, HL EHA guidance)

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

This article presents European Hematology Association (EHA) clinical practice guidelines for diagnosis, treatment, and follow-up of Hodgkin lymphoma (HL) in patients stratified by stage using PET/CT and the presence of risk factors. For early-stage favorable classic HL, it recommends two cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) followed by 20 Gy involved-site radiotherapy (IS-RT), with alternative risk-adapted regimens such as eBEACOPP (or procarbazine-free eBEACOPP) plus PET/CT-guided radiotherapy escalation to 30 Gy when PET/CT is positive. These guideline recommendations standardize risk-group allocation and therapy selection to improve outcomes while minimizing overtreatment in classic HL.

Eichenauer DA, André M, Borchmann P et al. · HemaSphere · (2026) · View on PubMed ↗ · Free PDF ↗

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

This NEJM report evaluated 10-year outcomes after CAR T-cell therapy with CTL019 (tisagenlecleucel), an autologous CD19-directed, 4-1BB-costimulated CAR T product, in 38 patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term follow-up showed durable lymphoma-free survival for a subset of patients and characterized late relapse and non-relapse-related outcomes over a decade. These findings inform expectations about durability and potential curative potential of tisagenlecleucel in real-world long-term management of B-cell lymphomas.

Ruella M, Paruzzo L, Chong ER et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Risk stratification in lymphoma (TI-CH, CD79B expression, pCR relapse TNBC)

Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.

This study measured CD79B protein expression by immunohistochemistry (IHC) in 590 de novo diffuse large B-cell lymphoma (DLBCL) cases and validated findings in an independent cohort of 272 cases, relating expression patterns to germinal center B-cell differentiation stages. It found a CD79B expression gradient across COO subtypes, with ABC-DLBCL showing the lowest expression and GCB and dark-zone signature-positive (DZsigpos) cases showing higher expression. The results support using CD79B expression patterns to better understand and potentially optimize the biology and responsiveness of CD79B-targeted antibody-drug conjugate therapy such as polatuzumab-vedotin.

Naoi Y, Chijimatsu R, Urata T et al. · Haematologica · (2026) · View on PubMed ↗ · Free PDF ↗

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

The study analyzed relapse risk after pathologic complete response (pCR) to neoadjuvant treatment in triple-negative breast cancer (TNBC) using the European GAMBIT real-world retrospective cohort of 2,457 patients. The key finding was that among patients achieving pCR, baseline clinical nodal status and tumor-infiltrating lymphocytes (TILs) independently predicted prognosis and relapse patterns. This could refine post-pCR risk stratification in TNBC to guide surveillance intensity and adjuvant decision-making.

Massa D, Foukakis T, Giacchetti S et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Tumor-infiltrating clonal hematopoiesis is associated with adverse clinical outcomes in diffuse large B-cell lymphoma.

This study analyzed tumor-infiltrating clonal hematopoiesis (TI-CH) in 304 treatment-naïve diffuse large B-cell lymphoma (DLBCL) patients using genome- and exome-wide sequencing of DLBCL biopsies and matched blood samples. The key finding was that TI-CH was present in 13.5% of cases and independently predicted worse disease progression and death, with tumor biopsies showing enrichment of an inflammatory myeloid gene expression signature. Clinically, the TI-CH-associated prognostic signature (CAPS) could refine risk stratification and identify patients who may benefit from more intensive or targeted management.

Chen J, Wu XY, Li X et al. · Blood cancer discovery · (2026) · View on PubMed ↗

Precision oncology modeling (virtual tumors, personalized combinations)

Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer.

This work developed “virtual tumors,” an interpretable mechanistic modeling framework to predict personalized therapeutic combinations for non-small cell lung cancer (NSCLC) adenocarcinoma. The key finding was that the model could use patient-specific molecular features to propose actionable drug combinations more efficiently than experimentally testing many regimens, aiming to address mutation-driven variability across patients. Scientifically, it supports a computational route to individualized combination therapy selection that could accelerate precision oncology trial design for NSCLC.

Clarke MA, Barker CG, Nicholls A et al. · Cancer research · (2026) · View on PubMed ↗

Neurodegeneration mechanisms (TDP-43 proteostasis, autophagy, ALS/FTD stress)

Reversible suppression of autophagy in a mouse model reveals neuronal resilience.

The study created a mouse model with rapidly reversible control of autophagy to test whether neuronal dysfunction from impaired autophagy can be restored. Suppressing autophagy caused proteome/transcriptome changes, inclusion body accumulation, and axonal swelling, which were largely ameliorated after autophagy restoration. This demonstrates neuronal resilience to reversible autophagy impairment and supports autophagy-targeted therapeutic strategies for neurodegenerative or injury-related conditions.

Eguchi T, Abe M, Tomita T et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

STMN2 protein depletion via translation deficits and stress granules in amyotrophic lateral sclerosis.

This study investigated how STMN2 (stathmin-2) protein depletion occurs in amyotrophic lateral sclerosis (ALS) using human and murine neuronal cell models under stress, focusing on mechanisms independent of TDP-43 nuclear condensation. The authors found that early acute high-magnitude stress suppresses human STMN2 via activated proteasomal degradation and that STMN2 loss can occur through TDP-43-independent pathways, with STMN2 levels being extremely labile during acute stress. Scientifically, it identifies stress-response mechanisms controlling STMN2 homeostasis beyond TDP-43, suggesting potential targets to modulate neuronal vulnerability in ALS.

Ellis BCS, Avila AS, Huang WP et al. · Brain : a journal of neurology · (2026) · View on PubMed ↗ · Free PDF ↗

Regional, functional and transcriptomic decoding of multidimensional brain structure alterations in obsessive-compulsive disorder.

The study used multimodal structural MRI to decode multidimensional brain alterations in obsessive-compulsive disorder (OCD) in 2,255 OCD patients and 2,264 controls across nine cortical and four subcortical phenotypes. It found spatially distinct regional changes, including default mode and frontoparietal network cortical curvature alterations and increased structural similarity network node degree in sensorimotor regions, alongside widespread volume reductions linked to OCD-related measures. This improves mechanistic brain-phenotype mapping in OCD and highlights specific structural network features for future biomarker and intervention development.

Cardoso Saraiva L, Sato JR, Sebenius I et al. · Nature communications · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Epigenetic Dysregulation of the Wnt/β-Catenin Pathway via FTO-m6A in the mPFC Contributes to Autism-Like Behaviors.

The study investigated whether epigenetic dysregulation of the Wnt/β-catenin pathway via FTO-mediated m6A affects autism-like behaviors in BTBR mice, focusing on Fto and the mRNA target Ctnnb1 (β-catenin). It found that Fto is upregulated in the medial prefrontal cortex (mPFC), that targeted Fto knockdown in the mPFC ameliorates core ASD-like behaviors, and that m6A methylome analysis implicates Ctnnb1 as a downstream pathway component. This links FTO–m6A regulation to β-catenin signalling in an ASD model and suggests a mechanistic target for therapeutic exploration.

Xue L, Zhang N, Zhao J et al. · Molecular neurobiology · (2026) · View on PubMed ↗

IRE1 regulates the proteostasis of TDP-43/TARDBP in ALS/FTD through ribosome-associated quality control.

The study investigated how inositol-requiring enzyme 1 (IRE1), an endoplasmic reticulum transmembrane protein, regulates TAR DNA-binding protein 43 (TDP-43/TARDBP) proteostasis in models relevant to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Genetic screening identified IRE1 as a suppressor of TDP-43 protein levels via ribosome-associated quality control (RQC) pathways. These findings link ER stress signaling through IRE1 to TDP-43 homeostasis and suggest a mechanistic target for ALS/FTD therapeutic strategies aimed at reducing pathogenic TDP-43 accumulation.

Liu D, Li Y, Huang S et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Plant development and mechanobiology (stomata, meristems, PPB)

A receptor-like mechanosensitive protein governs preprophase band positioning for asymmetric cell divisions and SC morphogenesis.

The study investigated the mechanism controlling preprophase band (PPB) positioning during asymmetric cell divisions and stomatal complex (SC) morphogenesis in maize, focusing on a receptor-like mechanosensitive protein. The maize receptor-like protein KAI1 was identified as a master regulator of subsidiary mother cell formation and as governing division-plane orientation in subsidiary mother cells in response to mechanosensitive cues. These results clarify how mechanotransduction is coupled to cell-cycle spatial patterning in plants, informing broader principles of asymmetric division control.

Duan Z, Duan W, Zhang Z et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Mitochondrial stress–epigenetics–longevity (C. elegans IRE1/FUBL-3)

FUBL-3/FUBP1 mediates mitochondrial stress-induced chromatin remodeling and longevity.

This study investigated how mitochondrial stress triggers chromatin remodeling and longevity in Caenorhabditis elegans, identifying FUBL-3 as the homolog of human FUBP1. The key finding was that FUBL-3 translocates to intestinal nuclei during stress, drives nucleosome remodeling and deacetylase-dependent chromatin condensation, and activates the mitochondrial unfolded protein response (UPRmt), with fubl-3 loss disrupting chromatin compaction and abolishing aspects of the stress response. These results establish FUBL-3/FUBP1 as a conserved nuclear effector linking mitochondrial stress to epigenetic regulation and longevity pathways.

Zhang Q, Dong H, Jiang Y et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

This study mapped functional circuitry of paraventricular nucleus (PVN) oxytocin (OXT) neurons in mice to determine how distinct projections regulate defensive behaviors during social threat. The key finding was that acute social defeat stress activates PVN OXT neurons, but projection-specific activity diverges: nucleus accumbens (NAc)-projecting PVN OXT neurons were inhibited during attacks while central amygdala (CeA)-projecting PVN OXT neurons were activated, using rabies virus tracing and circuit-specific Oxt manipulations. The work clarifies how OXT neuron projection topology encodes different defensive behavioral programs, informing circuit-level models of social threat processing.

Liu C, Wang X, Yao J et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

Steroid/sterol hormone control in plants (brassinosteroid–WUS)

Brassinosteroid signaling regulates shoot apical meristem homeostasis via orchestrating cytokinin and WUSCHEL activity.

This study examined how brassinosteroid (BR) signaling regulates shoot apical meristem (SAM) homeostasis in flowering plants by coordinating cytokinin and WUSCHEL (WUS) activity. The key finding was that BR signaling maintains SAM size and prevents premature termination by enhancing WUS expression and modulating WUS activity in the organizing center, acting synergistically with cytokinin through a BR transcriptional protein complex. These results connect a major sterol hormone pathway directly to stem-cell identity control, advancing mechanistic understanding of plant meristem regulation.

Wang X, Liu J, Zhao H et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

Protein aggregation determinants in ALS (sTDP-43 steric zippers)

Isoform-specific steric zippers drive aberrant assembly and mislocalization of shortened TDP-43.

This study investigated how isoform-specific steric zippers drive aberrant assembly and mislocalization of shortened TDP-43 (sTDP-43) in ALS, focusing on sTDP-43 splice isoforms that replace most of the prion-like domain with an 18-residue C-terminal tail. The key finding was that the short, isoform-specific carboxyl-terminal region forms steric zipper structures that promote insoluble aggregation and mislocalization despite lacking most of the canonical PrLD. Scientifically, it identifies structural determinants of sTDP-43 pathology that could guide therapeutic strategies targeting aggregation interfaces in ALS.

Copley KE, Dykstra MM, Miller MR et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

Alcoholic liver disease lipid remodeling (GPAM, mitochondrial dysfunction)

GPAM mediates mitochondrial dysfunction and the progression of alcoholic liver disease through lipid remodeling.

This study examined the role of glycerol-3-phosphateacyltransferase (GPAM) in alcoholic liver disease (ALD), assessing GPAM expression in patients and linking it to lipid remodeling and mitochondrial dysfunction. The key finding was that GPAM was down-regulated in ALD and that dysregulation increased toxic lipids (e.g., ceramide and lysophosphatidylcholine) while decreasing mitochondrial structural lipids such as cardiolipin, thereby promoting mitochondrial dysfunction and ALD progression. Clinically, GPAM and its lipid remodeling axis emerge as potential mechanistic targets for interventions aimed at restoring mitochondrial integrity in ALD.

Zhan Z, Liu X, Li Z et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

SUMOylation as cancer vulnerability (Pax6 sumoylation)

Inhibition of Pax6 sumoylation suppresses the tumorigenicity of pancreatic cancer cells.

The study examined whether inhibiting SUMO1-mediated sumoylation of the pancreatic cancer-relevant transcription factor Pax6 (p32 Pax6 at Lys-91/Lys-110) alters tumorigenicity in PANC-1 cells overexpressing p32 Pax6. Inhibition of Pax6 sumoylation suppressed the enhanced tumor development seen in immune-deficient mice injected with p32 Pax6–overexpressing PANC-1 cells. These findings suggest that targeting Pax6 sumoylation is a potential therapeutic strategy to reduce pancreatic cancer aggressiveness driven by Pax6 activity.

Xiao Y, Wang JM, Shan YY et al. · Cell death and differentiation · (2026) · View on PubMed ↗

mRNA-LNP vaccine immunology (innate/adaptive mechanisms)

Immunological mechanisms of mRNA vaccines for infectious diseases.

This review analyzed the immunological mechanisms by which nucleoside-modified mRNA delivered in lipid nanoparticles (mRNA-LNP) induces protective innate and adaptive immunity against infectious diseases, with emphasis on COVID-19. It highlights that vaccine efficacy depends on coordinated immune activation pathways and identifies current mechanistic knowledge gaps relevant to improving immunogenicity and tolerability. The work is significant for guiding the rational design of next-generation mRNA-LNP vaccines with better efficacy and safety profiles.

Locci M, Pardi N · Nature · (2026) · View on PubMed ↗

Exercise + GLP-1 vascular effects during weight maintenance

Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trial.

This prespecified secondary analysis of the S-LiTE trial studied 130 adults with obesity during 52 weeks of weight maintenance comparing exercise alone, liraglutide alone, or the combination after diet-induced weight loss. Exercise (alone or with liraglutide) reduced carotid intima-media thickness and systemic pro-inflammatory cytokines (interleukin-6 and interferon-γ), and combination therapy improved endothelial function biomarkers (sICAM-1, sVCAM-1, and tPA), whereas liraglutide alone showed no such improvements. Clinically, the results support exercise as a key driver of vascular anti-inflammatory benefits during maintenance and suggest additive vascular effects when combined with liraglutide.

Sandsdal RM, Holt J, Alkhefagie HGA et al. · Nature metabolism · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

COPD exacerbation biomarkers (ECM turnover, neutrophil elastase fragments)

Collagen- and elastin-derived biomarkers and acute severe exacerbations in COPD: a sub study of the CORTICO-COP trial.

This CORTICO-COP trial sub-study measured circulating extracellular matrix turnover and neutrophil protease neoepitopes (C5M, C6M, ELP-3, and CPa9-HNE) in plasma from COPD patients at hospital admission for acute severe exacerbations (n=299) and at day 30 stable follow-up (n=200). The study assessed whether these collagen/elastin-derived biomarkers and neutrophil elastase–generated fragments predict time to readmission with AECOPD or all-cause mortality. If validated, these biomarkers could improve risk stratification for acute exacerbations in COPD using minimally invasive blood tests.

Høgdall AS, Bülow Sand JM, Vognsen AK et al. · Scientific reports · (2026) · View on PubMed ↗ · Free PDF ↗

Immune thrombocytopenia thrombopoiesis (S100A8/A9, TLR4/JNK/GATA1)

Neutrophil-derived S100A8/A9 impairs megakaryocyte maturation in immune thrombocytopenia.

The study investigated how neutrophil-derived S100A8/A9 impairs megakaryocyte maturation in immune thrombocytopenia (ITP) using single-cell and spatial transcriptomics, primary CD34+-derived megakaryocyte cultures, and mouse ITP models. It found that S100A8/A9 activates TLR4 and the JNK/c-Jun signaling axis, repressing the megakaryocyte master regulator GATA1 and reducing polyploidization, maturation markers, and platelet-like particle release; tasquinimod treatment or TLR4 inhibition partially restored maturation endpoints. These mechanistic and intervention data identify the S100A8/A9–TLR4–JNK/c-Jun–GATA1 pathway as a therapeutic target to improve thrombopoiesis in ITP.

Qi J, Zhou M, Yin J et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Ciliary coordination biology (RGS22 radial spoke)

RGS22 is a metazoa-specific radial spoke component required for coordinated ciliary beating.

This study examined the role of the metazoa-specific radial spoke component RGS22 in coordinated motile ciliary beating by analyzing mouse Rgs22-deficient cilia. Loss of Rgs22 produced ultrastructural defects in radial spoke 1/2 complexes (deformed RS1 and disorganized outer dynein arms) along with impaired planar polarity and unsynchronized ciliary beating. The findings establish RGS22 as a key evolutionary metazoan subunit required for proper radial spoke function and tissue-level ciliary coordination.

Fang A, Luo J, Xu H et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Biomarkers of immune checkpoint resistance (melanoma proteomics/cytometry)

Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.

This study profiled blood from 250 metastatic melanoma patients receiving immune checkpoint blockade (ICB) using plasma proteomics (>2900 proteins) and high-dimensional mass cytometry of peripheral blood lymphocytes across serial time points. It aimed to identify circulating protein and immune-cell signatures associated with immunotherapy resistance, including primary resistance and early progression. The work is significant because scalable multimodal blood biomarkers could enable earlier treatment switching and reduce unnecessary toxicity in patients unlikely to benefit from ICB.

Wright SJ, Zamora I, Parikh M et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Parkinson’s disease genetics (MAPT haplotypes)

Exploring MAPT-containing H1 and H2 haplotypes in Parkinson’s disease across diverse populations.

This genetic association study analyzed MAPT-containing H1 and H2 haplotypes at the 17q21.31 locus in 20,507 Parkinson’s disease patients and 11,841 controls across eleven ancestries. It evaluated haplotype and subhaplotype frequencies to clarify how the H1 risk haplotype (present across ancestries) and the H2 inverted haplotype (enriched in European ancestry) relate to PD risk beyond European populations. The results are important for improving ancestry-inclusive understanding of MAPT genetic risk architecture in Parkinson’s disease.

Reyes-Pérez P, Hor JW, Toh TS et al. · NPJ Parkinson’s disease · (2026) · View on PubMed ↗

Human-specific necrosis pharmacology (TRPM4 activation by Necrocide 1)

Structural mechanism of Necrocide 1 activation of human TRPM4 that triggers necrosis by sodium overload.

The study elucidated the structural mechanism by which the small molecule Necrocide 1 (NC1) activates human TRPM4 to trigger necrosis via sodium overload (NECSO). Using single-particle cryo-EM, electrophysiology, and cell death assays, it identified the NC1-binding site and key molecular determinants for channel activation and explained why mouse TRPM4 is insensitive to NC1. This mechanistic insight is significant for understanding human-specific TRPM4 pharmacology and for developing targeted necrosis-modulating strategies.

Teixeira-Duarte CM, Fu W, Zeng W et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Microbiome–metabolite–cancer axis (Fusobacterium/decanoic acid, neutrophils)

Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels.

This randomized, double-blind, placebo-controlled multicenter trial studied pasteurized Akkermansia muciniphila MucT in 142 adults with metabolic syndrome (with or without prediabetes), stratifying by baseline gut Akkermansia levels. Four months of daily pasteurized A. muciniphila MucT (30 billion cells per capsule) did not change the primary endpoint of whole-body insulin sensitivity (Matsuda index) versus placebo in intention-to-treat analysis, although exploratory analyses suggested earlier effects on GLP-1 production and related metabolic measures. The results indicate that this specific probiotic preparation may have limited impact on insulin sensitivity at the trial’s primary endpoint, informing future selection of strains, dosing, and patient baseline microbiome context.

Suenaert P, Segers A, Rymenans L et al. · Gut microbes · (2026) · View on PubMed ↗ · Free PDF ↗

Fusobacterium periodonticum promotes colorectal tumorigenesis via decanoic acid-driven neutrophil chemotaxis.

This study investigated how Fusobacterium periodonticum promotes colorectal tumorigenesis through decanoic acid–driven neutrophil chemotaxis by integrating metagenomic and metabolomic analyses of clinical cohorts with single-cell transcriptomics. It found F. periodonticum enriched in colorectal cancer patients, correlated with elevated decanoic acid, and showed tumor tissue neutrophil enrichment characterized by high CXCL8 expression and activation of neutrophil-rel pathways. The findings link a specific gut microbe–metabolite–neutrophil axis to colorectal cancer progression, suggesting potential targets in the decanoic acid/chemotaxis pathway for therapy or prevention.

Jia X, Jiang L, Gong Y et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Post-thrombectomy stroke therapy (tirofiban)

This multicentre, double-blind, randomised controlled trial in China studied intra-arterial tirofiban (a glycoprotein IIb/IIIa receptor antagonist) in adults with acute ischaemic stroke due to anterior-circulation large-vessel occlusion who achieved successful endovascular reperfusion after thrombectomy. Tirofiban improved functional outcomes compared with placebo and had an acceptable safety profile in this post-thrombectomy setting. These findings support adding GP IIb/IIIa blockade after successful thrombectomy to increase the likelihood of functional independence in stroke patients who otherwise remain at risk of poor recovery.

Huang H, Xu S, Qin T et al. · Lancet (London, England) · (2026) · View on PubMed ↗

Heart failure therapeutics (ghrelin agonist/calcium-sensitizing inotrope AC01)

This phase 1b/2a, randomised, double-blind, placebo-controlled study evaluated the oral ghrelin receptor agonist and calcium-sensitising inotrope AC01 in adults aged 18–80 years with heart failure with reduced ejection fraction (LVEF ≤40%) who had a transvenous implantable cardioverter defibrillator for primary prevention. AC01 was assessed for safety and pharmacokinetics and showed exploratory signals of efficacy on cardiac function compared with placebo. If confirmed in larger trials, AC01 could provide a new inotrope class for HFrEF that targets ghrelin receptors while potentially reducing adverse effects seen with existing inotropes.

Lund LH, Barandiarán Aizpurua A, Bollano E et al. · Lancet (London, England) · (2026) · 1 citations · View on PubMed ↗

Severe asthma remission and real-world burden (registry analysis)

Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry.

This multicentre observational cross-sectional analysis used data from 13,455 adults with severe asthma in the European Severe Heterogeneous Asthma Registry (SHARP) to examine remission prospects and real-world disease burden across Europe. The study identified factors associated with lower or higher likelihood of achieving severe asthma remission and quantified ongoing morbidity and healthcare use despite treatment advances including biologics. These registry-based insights can guide clinicians and health systems in setting realistic remission expectations and targeting modifiable drivers of persistent severe disease.

Fouka E, Bansal AT, Håkansson KEJ et al. · The Lancet. Respiratory medicine · (2026) · View on PubMed ↗

Microbiota metabolite effects on insulin/mitochondria (phenylacetylation, SIRT3)

Gut microbiota-derived lysine phenylacetylation impairs mitochondrial function and is alleviated by SIRT3.

This mechanistic study investigated how gut microbiota-derived phenylacetylation (Kpaa) affects hepatic mitochondrial function and insulin signaling in mouse models of high-fat-diet-induced obesity and whether the mitochondrial deacetylase SIRT3 can alleviate these effects. Gut-derived phenylacetylation levels were elevated in obese mice, reduced by SIRT3, and phenylacetylation disrupted mitochondrial function and impaired insulin signaling. The work links a specific microbiota metabolite pathway (phenylacetic acid/phenylalanine-dependent PAA) to mitochondrial dysfunction via a defined lysine post-translational modification, suggesting SIRT3 and Kpaa as potential therapeutic targets.

Du W, Xu JY, Li Y et al. · Cell metabolism · (2026) · View on PubMed ↗

Human developmental patterning (primitive streak, gastrulation maps)

Epiblast diversification and blood formation in a human pregastrula.

This study characterized early human gastrulation by generating a high-resolution spatial transcriptomic map of a human embryo at Carnegie stage 6 (~13–14 days post-conception) when the primitive streak is not yet visible. It identified an anterior visceral endoderm-like hypoblast population and a trifurcated epiblast trajectory leading toward amnion, primitive streak, and node/prechordal plate/notochord (axial mesoderm) at later stages. These findings improve mechanistic understanding of human pregastrula development and the emergence of germ-layer lineages.

Xiao Z, Gong Y, Yang X et al. · Nature · (2026) · View on PubMed ↗

Reconstituting human primitive streak formation through extra-embryonic cell coordination.

This study used a defined human embryonic stem cell (ESC) co-culture system with engineered extra-embryonic cell types (mimicking amniotic ectoderm, trophoblast, and extra-embryonic mesoderm) and microengineering approaches to reconstitute primitive streak formation in vitro. Coordinated interactions with specific extra-embryonic lineages improved the organization and emergence of primitive streak-like structures compared with ESCs alone. These findings advance experimental control of early human developmental patterning and provide a platform to dissect how extra-embryonic tissues regulate gastrulation programs.

Shen Q, Zhang X, Chen N et al. · Cell · (2026) · View on PubMed ↗

Future-oriented behavioral interventions for cardiovascular health

Adherence to the Mediterranean diet and risk of pancreatic cancer: an analysis of 2.3 million participants in the Pooling Project of Prospective Studies of Diet and Cancer (DCPP).

Using pooled prospective data from 2,315,406 participants across 23 cohorts in the DCPP, the study assessed whether adherence to the Mediterranean diet is associated with pancreatic cancer risk. The analysis quantified incident pancreatic cancer cases (10,748) over long follow-up and evaluated the diet–cancer association across cohorts. This large-scale epidemiologic evidence helps resolve inconsistent prior findings and supports identification of modifiable dietary risk factors for pancreatic cancer prevention.

Shen Q, Mobley C, Wang M et al. · European journal of epidemiology · (2026) · View on PubMed ↗

The effects of episodic future thinking interventions on cardiovascular health behaviors: A meta-analysis.

This meta-analysis synthesized evidence from episodic future thinking interventions aimed at improving cardiovascular health behaviors in participants across included studies. Overall, episodic future thinking showed beneficial effects on cardiovascular health behaviors compared with control conditions. The results support future-oriented cognitive interventions as a potentially scalable behavioral strategy to improve adherence to cardiovascular prevention and management behaviors.

You J, Wan Z, Huang Z et al. · International journal of nursing studies · (2026) · View on PubMed ↗

Traditional medicine for vascular integrity in CCM (CDDP)

Compound Danshen Dripping Pills retards the progression of cerebral cavernous malformations via strengthening vascular integrity and ameliorating inflammatory response.

This preclinical study investigated Compound Danshen Dripping Pills (CDDP), a traditional Chinese medicine, for its ability to retard progression of cerebral cavernous malformations (CCMs) by strengthening vascular integrity and reducing inflammation. Using chemical characterization by UPLC-MS/MS and experimental CCM models, CDDP treatment was associated with reduced CCM progression alongside improved vascular integrity and ameliorated inflammatory responses. These data provide mechanistic rationale for CDDP as a candidate non-surgical therapy to slow CCM disease progression and potentially reduce bleeding risk.

Chen L, Zheng W, Ma J et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology · (2026) · View on PubMed ↗

Mitochondrial regulators in cancer (prohibitin PHB1/PHB2 review)

Prohibitins in cancer: Multifaceted regulators of mitochondrial homeostasis, oncogenic signaling, tumor microenvironment, and therapeutic resistance.

This narrative review summarized the roles of prohibitin proteins PHB1 and PHB2 as multifunctional regulators of mitochondrial homeostasis, oncogenic signaling, tumor microenvironment interactions, and therapeutic resistance across cancer types. It highlights how PHB1/PHB2 scaffold complexes and their subcellular localization enable integration into multiple signaling pathways, including activation of the RAS–RAF–MEK–ERK cascade. By consolidating current mechanistic and therapeutic evidence, the review identifies PHBs as potential biomarkers and targets for future cancer treatment strategies.

Fang L, Yang Y, Tian X et al. · Cancer genetics · (2026) · View on PubMed ↗

Peanut allergy prevention and immunotherapy (early introduction)

Prevention and Treatment of Peanut Allergy.

This review article evaluated evidence for prevention and treatment strategies for peanut allergy, focusing on early peanut introduction and peanut immunotherapy. Early introduction of peanut protein substantially reduces allergy prevalence, and peanut immunotherapy in younger children (about ages 1–3 years) shows higher clinical remission rates than later initiation. The clinical significance is that population-level early feeding and age-appropriate immunotherapy could meaningfully reduce peanut allergy burden and improve long-term outcomes.

Du Toit G, Lack G · The New England journal of medicine · (2026) · View on PubMed ↗

Extracellular mitochondria in systemic injury after TBI

Extracellular Mitochondria Mediate Endothelial Injury After Traumatic Brain Injury.

The study investigated whether extracellular mitochondria (exMt) mediate endothelial injury after traumatic brain injury (TBI) by measuring exMt in peripheral blood of TBI patients and in TBI mouse models. exMt were abundant in the peripheral blood after severe TBI and were used to test their causal role in driving secondary endothelial dysfunction beyond the primary injury site. These findings identify extracellular mitochondria as a mechanistic link between TBI and systemic vascular injury, suggesting potential biomarkers or therapeutic targets to limit secondary damage.

Tang L, Liu Y, Pang K et al. · Arteriosclerosis, thrombosis, and vascular biology · (2026) · View on PubMed ↗ · Free PDF ↗

Pulmonary fibrosis targeted degradation delivery (inhalable PROTAC nanococktail)

Inhalable Polymeric PROTAC Nanococktail for Targeted Protein Degradation in Idiopathic Pulmonary Fibrosis.

This study developed and tested an inhalable enzyme-activated polymeric PROTAC nanococktail for targeted protein degradation in idiopathic pulmonary fibrosis (IPF) models. The key finding was that the inhalable, lesion-retentive PROTAC platform improved pulmonary delivery and enabled degradation of disease-driving proteins within fibrotic lung tissue, overcoming limitations of conventional PROTAC delivery in multicellular profibrotic networks. This provides a translational strategy for treating IPF by combining localized inhalation with controlled PROTAC activation to suppress pathological signaling and extracellular matrix deposition.

Tan Q, Zhao Y, Zhang Y et al. · Journal of the American Chemical Society · (2026) · View on PubMed ↗

Genomic reanalysis automation for rare disease (Talos)

Automated reanalysis of genomic data for rare disease diagnostics at scale.

The study created Talos, an open-source automated tool for iterative reanalysis of genomic data for rare disease diagnostics, and evaluated it in 1,089 individuals with rare disease using trio-based analysis. Talos achieved 90% identification of known diagnoses and reduced variant burden to about one variant per 200 cases by integrating dynamically updated gene–disease and variant-level evidence with inheritance-aware filtering. This supports scalable, high-specificity genomic reanalysis workflows that can improve diagnostic yield while reducing manual effort.

Welland MJ, Ahlquist KD, De Fazio P et al. · Nature medicine · (2026) · View on PubMed ↗ · Free PDF ↗

STING activation sequence-function landscape

The mutational landscape of STING-induced immunity.

This article investigated the sequence determinants governing STING (stimulator of interferon genes) activation by mapping how STING variants affect function. Using a massively parallel sequence-function assay, the authors systematically charted STING (in)activation across sequence elements, linking ligand-induced structural transitions and downstream signaling outputs to specific sequence features. Scientifically, it provides a mutational landscape that can guide interpretation of STING variants and inform therapeutic targeting of STING-driven immunity.

Zhang B, Xu P, Meng Y et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Alternate genetic code / proteome diversity (alternate RNA decoding)

Alternate RNA decoding results in stable and abundant proteins in mammals.

This study analyzed whether alternate RNA decoding (deviations from the genetic code) produces stable, abundant proteins in mammals using deep proteomic, transcriptomic, and genomic data from over 1,000 human samples across 6 cancer types and 26 healthy tissues. It identified 8,746 unique substitutions in proteins derived from 1,767 genes (with 1,955 confidently localized sites), including substitutions shared across samples and others that were tissue- or cancer-specific. The work expands the functional relevance of non-canonical translation by showing that alternate decoding can contribute to proteome diversity in vivo.

Tsour S, Machné R, Leduc A et al. · Nature · (2026) · View on PubMed ↗

ecDNA segregation mechanisms (H3K27ac readers)

Cis and trans regulatory mechanisms of extrachromosomal DNA segregation.

The study examined how extrachromosomal DNA (ecDNA) segregates during mitosis by testing cis and trans regulatory mechanisms governing ecDNA–chromosome interactions. It found that ecDNAs tether to mitotic chromatin marked by histone H3 lysine 27 acetylation (H3K27ac), and that bromodomain proteins acting as H3K27ac readers stabilize ecDNA–chromosome binding in a context-dependent, complementary manner. This clarifies the molecular basis of ecDNA segregation and provides targets (e.g., H3K27ac readers) for probing ecDNA-driven cancer heterogeneity.

Xie Y, Lim JYS, Liu W et al. · Nature cell biology · (2026) · View on PubMed ↗ · Free PDF ↗

Microbial antibiotic biosynthetic genetics (Streptomyces megacluster)

A Streptomyces megacluster encodes synergistic biotin-targeting antibiotics.

This study investigated the biosynthetic genetics of a Streptomyces megacluster that produces synergistic biotin-targeting antibiotics. It found that Streptomyces species encode a conserved megacluster producing four natural product families—stravidins, acidomycin, dapamycins, and α-Me-KAPA—along with the biotin-binding protein streptavidin, indicating coordinated multi-metabolite antibiotic action. Scientifically, it reveals a genetic architecture for synergistic antibiotic systems and provides a framework for discovering and engineering multi-component antimicrobials.

Gordzevich R, Xu M, Wang W et al. · Nature · (2026) · 2 citations · View on PubMed ↗

GPCR signaling control tools (β-arrestin modulators)

Small-molecule modulation of β-arrestins.

The study developed and characterized small-molecule inhibitors that selectively modulate β-arrestin function across GPCR signalling systems. The key finding was that the inhibitors disrupt β-arrestin engagement with activated GPCRs (via a defined mechanism supported by integrated pharmacological, biochemical, biophysical, and structural analyses). This provides the first direct chemical tools to control β-arrestin activity, enabling more precise dissection of GPCR signalling pathways and potential therapeutic targeting of β-arrestin-dependent biology.

Kahsai AW, Pakharukova N, Kwon HY et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

In vitro immune cell differentiation (Tfr cells, TGF-β/IL-2)

TGF-β and IL-2 differentially shape T follicular regulatory cell differentiation and stability in vitro.

The study developed an in vitro differentiation protocol for mouse CD4+ T cells to generate CXCR5+FoxP3+ T follicular regulatory (Tfr) cells and tested how TGF-β and IL-2 shape their differentiation and stability. The key finding was that TGF-β and IL-2 differentially regulate Tfr cell fate and maintenance, producing Tfr cells with a Bcl6hi PD-1hi CD25lo GITRint phenotype distinct from related regulatory T cell subsets. This provides controlled experimental conditions to dissect cytokine control of Tfr biology, informing strategies to modulate germinal center responses.

Bach L, Chang Y, Arteaga Transito O et al. · Cellular & molecular immunology · (2026) · View on PubMed ↗ · Free PDF ↗

Metabolomics and brain health (cognition/MRI, Rotterdam Study)

The blood metabolome of brain health in midlife and influences of genes, microbiome and exposome.

The study assessed associations between 991 blood metabolites and brain health outcomes (cognition and MRI measures) in 1,082 dementia-free midlife participants from the Rotterdam Study, and then replicated cognition-associated metabolites in two older-adult cohorts. The key finding was that genetic variation, lifestyle, comorbidities, medication, and gut microbiota each contributed to metabolite variance, and specific metabolites were linked to cognition and brain imaging measures. This supports the concept that the peripheral blood metabolome—shaped by genes and exposures—can reflect brain health and may help identify modifiable risk pathways for neurodegenerative disease.

Ahmad S, Wu T, Arnold M et al. · Nature aging · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

TB progression signatures in airway immune cells (household contacts)

Airway immune signatures of protection and disease progression in recent human tuberculosis household contacts.

The study profiled airway immune responses at single-cell resolution in bronchoalveolar lavage from recent tuberculosis (TB) household contacts who either controlled infection or progressed to active TB, and compared them with patients with active TB at diagnosis. The key finding was that both type I IFN-dependent and IFN-independent neutrophil signatures distinguish active TB and TB progressors, indicating different neutrophil programs associated with disease progression. This identifies airway immune signatures that may predict progression versus protection and inform future TB risk stratification strategies.

Branchett WJ, Kim JW, Shields J et al. · Nature immunology · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Viral emergence risk via receptor usage (merbecoviruses)

Addressing the zoonotic threat of merbecoviruses.

The study reviewed and synthesized evidence on merbecoviruses, focusing on their zoonotic threat, ecology, and receptor usage beyond MERS-CoV. The key finding was that merbecoviruses have expanded receptor repertoires, with some members using dipeptidyl peptidase 4 as well as angiotensin-converting enzyme 2 or aminopeptidase N, increasing potential host range and cross-species transmission. This helps frame how receptor diversity may drive emergence risk and guides surveillance and therapeutic research for merbecoviruses.

Li X, Kang M, Jiao XY et al. · Nature microbiology · (2026) · View on PubMed ↗

Public health outbreak reporting (Bundibugyo virus DRC)

Bundibugyo Virus Disease in 2026 - Clinical and Public Health Responses.

This 2026 clinical and public health report reviewed the Bundibugyo virus disease outbreak in the Democratic Republic of Congo and the challenges in detection, diagnosis, clinical management, and response in resource-limited settings. The key finding was that the 2026 outbreak underscored persistent gaps in rapid case identification and laboratory confirmation needed to control filovirus spread. Scientifically and clinically, the article highlights actionable priorities—faster diagnostics, isolation, and coordinated public health response—to reduce mortality in future Bundibugyo virus outbreaks.

Sullivan NJ · The New England journal of medicine · (2026) · View on PubMed ↗

Cardiac death prediction from ECG (deep learning SCD biomarker)

Dietary cholesterol activates a Ral-dependent pathway driving LDLR turnover.

This study investigated how dietary cholesterol regulates hepatic low-density lipoprotein receptor (LDLR) turnover by identifying a Ral-dependent trafficking pathway. It found that chronic dietary cholesterol activates Ral GTPases (via increased RAS activity), rerouting LDLR to lysosomal degradation and inhibiting recycling independently of transcriptional regulation and PCSK9. These findings clarify a post-transcriptional cholesterol-sensing mechanism that could be exploited to modulate LDLR levels and cholesterol homeostasis therapeutically.

Feng X, Zhang S, Wang Y et al. · Nature · (2026) · View on PubMed ↗

An ECG biomarker for sudden cardiac death discovered with deep learning.

This study developed and validated a deep learning ECG biomarker for sudden cardiac death using a Swedish regional dataset linking all ECGs to death certificates. The model identified a high-risk subgroup (2.2% of the sample) with a 7.0% annual sudden cardiac death rate, outperforming risk stratification based on reduced left ventricular ejection fraction (LVEF), which had a lower annual rate (4.6%) in a larger low-risk group. Clinically, this provides a scalable, ECG-based approach to improve sudden cardiac death prediction and potentially reduce inappropriate defibrillator use.

Obermeyer Z, Schubert A, Ross J et al. · Nature · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Generated automatically on June 26, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.

← All Trending Digests

PubMed Trending Research Digest — June 26, 2026

PubMed Trending Research Digest — June 26, 2026

Overview

Antipsychotic response biomarkers (neurochemistry)

Cryo-electron microscopy structures of human cone visual pigments.

Neurometabolites and Antipsychotic Response in Psychosis: A Mega-Analysis.

Antiplatelet therapy optimization in PCI (bleeding vs efficacy)

A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis.

Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis.

Inflammation-modified cardiovascular risk (Lp(a), CAD, aortic stenosis)

Regional fat distribution as a determinant of mortality in populations with left ventricular systolic dysfunction: challenging the obesity paradox.

Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis.

Cutaneous adverse drug reactions (immune/biologic therapies)

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Targeted radiopharmaceutical therapy (alpha therapy, PET imaging)

FOLR1-targeted actinium-225-based alpha-particle therapy eliminates ovarian cancer.

Genetics of alcohol toxicity and neuroinflammation

Common human ALDH1B1 and ALDH2 variants increase neuroinflammatory response to a single ethanol dose in mice.

Mucosal immunity and viral infection prevention (IgA, norovirus)

IgA is necessary and sufficient to prevent norovirus infection in mice.

Temperature and developmental stage govern intestinal susceptibility to human coronavirus 229E.

Spatial immunology in autoimmune disease (RA macrophage–fibroblast niche)

Transferrin in combination with induction chemotherapy improves outcomes in mouse models of acute myeloid leukemia.

Host–virus post-translational control of antiviral restriction (SMCHD1, HSV-1)

SUMOylation and ubiquitination reciprocally regulate SMCHD1 antiviral activity against herpes simplex virus 1.

Multiplex protein mapping / proteome tagging methods

A pilot study for whole proteome tagging in Caenorhabditis elegans.

Fungal pathogen life-cycle regulation (meiosis in Cryptococcus)

Identification of a master regulator Msd1 that governs meiotic entry in a global basidiomycete pathogen.

Viral engineering and genome expression mapping (SARS-CoV-2 extra genes)

Extra gene coding capacity of SARS-CoV-2 provides a virus engineering platform for in vitro and in vivo applications.

Tumor suppressor–metabolism axes in cancer (p53–METTL5–mitochondria)

p53 overrides METTL5 loss-induced tumor suppression via mitochondrial respiration.

Cancer immunotherapy engineering (TCR-mimic bispecifics, CAR T targets)

AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy.

TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy.

Inflammasome regulation and phase separation (ASC, DDX6)

RNA helicase DDX6 governs ASC speck formation in P-bodies and the transition to stress granules via phase separation during inflammasome activation.

Cancer immunometabolism and cachexia (immune-driven catabolism)

An immunological panacea for cancer-related cachexia.

AI/biomarkers for immunotherapy response (imaging, proteomics, spatial immune states)

Breastfeeding shapes a unique tumor-immune landscape in pregnancy-associated breast cancer from GEICAM-EMBARCAM study.

Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.

Spatial immune microenvironments in metastasis (brain metastases, macrophage escape)

Spatial immune atlas of breast cancer brain metastasis reveals CD163+ macrophage reprogramming associated with immune escape.

Pulmonary arterial hypertension treatment de-escalation (sotatercept/prostacyclin)

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept.

JAK inhibition and immune remodeling in inflammatory skin disease (PPP)

Ivarmacitinib is associated with rapid clinical improvement and immune remodeling in palmoplantar pustulosis: A multi-center, single-arm clinical trial.

CAR-T optimization (lymphodepletion regimens, long-term outcomes)

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Type 2 inflammation therapeutics (dupilumab, eosinophilic gastritis)

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial.

Obesity epidemiology and inequality (UK trends)

Whole-population trends in obesity across dimensions of inequality in England, 2019-25: a retrospective, longitudinal cohort study of 54 million adults.

CT-Assessed Sarcopenia Combined with Laboratory Inflammatory Markers for Outcome Prediction in Critically Ill, Pulmonary, and Geriatric Patients: A Systematic Review and Meta-Analysis.

GLP-1 and body composition / lean mass preservation

Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies.

GLP-1 and renal outcomes in obesity with CKD/hypertension

Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.

H. pylori eradication regimen optimization (antibiotic resistance, lactoferrin)

Helicobacter pylori Eradication in the Era of Rising Antibiotic Resistance: A Randomized Controlled Comparison of Clarithromycin- and Levofloxacin-Based Triple Therapy with or without Lactoferrin.

Digital/scalable psychotherapy for chronic pain (CBT-CP delivery)

Self-Directed vs Clinician-Delivered Cognitive Behavioral Therapy for Chronic Pain: A Randomized Clinical Trial.

Cardiovascular trial endpoints (right ventricle metrics)

Right Ventricular Metrics as End Points in Clinical Trials: A Review.

Neuroimaging-guided neuromodulation (aTMS targeting)

Connectivity- vs Scalp-Based Targeting of Accelerated Transcranial Magnetic Stimulation for Depression: A Randomized Clinical Trial.

Genome editing in human embryos (base editing, NANOG)

Base editing reveals an essential role for NANOG in human embryogenesis.

Bispecific therapy in hematologic malignancy (teclistamab regimens)

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Long-term CAR T durability and guidelines (tisagenlecleucel, HL EHA guidance)

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

Risk stratification in lymphoma (TI-CH, CD79B expression, pCR relapse TNBC)

Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Tumor-infiltrating clonal hematopoiesis is associated with adverse clinical outcomes in diffuse large B-cell lymphoma.